Literature DB >> 14751627

The combination of mitotic and Ki-67 indices as a useful method for predicting short-term recurrence of meningiomas.

Jun A Takahashi1, Tetsuya Ueba, Nobuo Hashimoto, Yasuaki Nakashima, Naomi Katsuki.   

Abstract

BACKGROUND: The most relevant factor in the progression-free survival (PFS) of patients with meningiomas is the malignant grade. However, using only the current World Health Organization (WHO) definition that does not consider precise quantitative indicators, an unequivocal diagnosis of the malignant grade is difficult. In our retrospective study of the PFS of meningioma patients, we focused on mitoses and the Ki-67 staining index of tumor specimens obtained at the initial surgery. METHODS AND
RESULTS: A total of 349 patients with intracranial meningioma, operated between 1978 and 2000, were followed for a mean of 7 years. According to the mitotic index (MI), we classified them into 3 groups. In Group A (n = 326), slide-mounted tumor samples exhibited no mitoses; in Group B (n = 15) there were fewer than 4 mitoses, and in Group C (n = 8) 4 or more mitoses were seen per 10 high-power fields (HPF). The estimated 5-year PFS rates in Groups A, B, and C were 93%, 10%, and 13% respectively. The mean PFS for Group A was 148 months; in Groups B and C the median PFS was 43 and 16 months, respectively. A Ki-67 staining index (SI) of less than 1% corresponded with no mitosis, while an SI exceeding 5% was indicative of the presence of mitoses.
CONCLUSION: In meningioma patients, no mitoses and/or a Ki-67 SI <1% signals a favorable outcome. An SI >5% or the presence of mitoses, even fewer than 4 in 10 HPF, is suggestive of a short PFS irrespective of other pathologic features. We suggest that in combination, assay of the Ki-67 SI and the MI represents a reliable, quantitative tool for predicting PFS in meningioma patients.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14751627     DOI: 10.1016/s0090-3019(03)00575-5

Source DB:  PubMed          Journal:  Surg Neurol        ISSN: 0090-3019


  8 in total

1.  Associations of meningioma molecular subgroup and tumor recurrence.

Authors:  Mark W Youngblood; Danielle F Miyagishima; Lan Jin; Trisha Gupte; Chang Li; Daniel Duran; Julio D Montejo; Amy Zhao; Amar Sheth; Evgeniya Tyrtova; Koray Özduman; Francesco Iacoangeli; Matthieu Peyre; Julien Boetto; Matthew Pease; Timuçin Avşar; Anita Huttner; Kaya Bilguvar; Türker Kilic; M Necmettin Pamir; Nduka Amankulor; Michel Kalamarides; E Zeynep Erson-Omay; Murat Günel; Jennifer Moliterno
Journal:  Neuro Oncol       Date:  2021-05-05       Impact factor: 12.300

2.  Osteopontin expression is a valuable marker for prediction of short-term recurrence in WHO grade I benign meningiomas.

Authors:  Kuan-Yin Tseng; Min-Huey Chung; Huey-Kang Sytwu; Horng-Mo Lee; Kuan-Yu Chen; Chen Chang; Chih-Kung Lin; Che-Hung Yen; Jia-Hong Chen; Gu-Jiun Lin; Hsin-I Ma; Yi-Shian Yeh; Da-Tong Ju; Ming-Ying Liu; Dueng-Yuan Hueng
Journal:  J Neurooncol       Date:  2010-04-29       Impact factor: 4.130

3.  18F-FDG PET in the assessment of tumor grade and prediction of tumor recurrence in intracranial meningioma.

Authors:  Jeong Won Lee; Keon Wook Kang; Sung-Hye Park; Sang Mi Lee; Jin Chul Paeng; June-Key Chung; Myung Chul Lee; Dong Soo Lee
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-04-18       Impact factor: 9.236

4.  Cyclin D1 immunoreactivity in meningiomas.

Authors:  Sanja Milenković; Tatjana Marinkovic; Milan B Jovanovic; Slavisa Djuricic; Ivana I Berisavac; Iva Berisavac
Journal:  Cell Mol Neurobiol       Date:  2008-04-01       Impact factor: 5.046

5.  Successful radiopeptide targeting of metastatic anaplastic meningioma: case report.

Authors:  Amir Sabet; Hojjat Ahmadzadehfar; Ulrich Herrlinger; Winfried Wilinek; Hans-Jürgen Biersack; Samer Ezziddin
Journal:  Radiat Oncol       Date:  2011-08-12       Impact factor: 3.481

6.  Grading meningioma: a comparative study of thallium-SPECT and FDG-PET.

Authors:  Sachi Okuchi; Tomohisa Okada; Akira Yamamoto; Mitsunori Kanagaki; Yasutaka Fushimi; Tsutomu Okada; Moritaka Yamauchi; Masako Kataoka; Yoshiki Arakawa; Jun C Takahashi; Sachiko Minamiguchi; Susumu Miyamoto; Kaori Togashi
Journal:  Medicine (Baltimore)       Date:  2015-02       Impact factor: 1.889

7.  Outcomes of Preserving the Hypertrophic Arachnoid Membrane in the Brain-meningioma Interface: Long-term Follow-up.

Authors:  Yoko Nakasu; Koichi Mitsuya; Satoshi Nakasu; Shoichi Deguchi; Nakamasa Hayashi
Journal:  Neurol Med Chir (Tokyo)       Date:  2021-10-29       Impact factor: 1.742

8.  Atypical Histological Features as Risk Factors for Recurrence in Newly Diagnosed WHO Grade I Meningioma.

Authors:  Keitaro Chiba; Takashi Sugawara; Daisuke Kobayashi; Akihito Sato; Yasuhiro Murota; Taketoshi Maehara
Journal:  Neurol Med Chir (Tokyo)       Date:  2021-09-01       Impact factor: 1.742

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.